JP2017527615A - 線維化疾患及び癌を治療するための組成物及び方法 - Google Patents

線維化疾患及び癌を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2017527615A
JP2017527615A JP2017531467A JP2017531467A JP2017527615A JP 2017527615 A JP2017527615 A JP 2017527615A JP 2017531467 A JP2017531467 A JP 2017531467A JP 2017531467 A JP2017531467 A JP 2017531467A JP 2017527615 A JP2017527615 A JP 2017527615A
Authority
JP
Japan
Prior art keywords
cancer
lyn
fibrosis
subject
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017531467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527615A5 (enExample
Inventor
アンドジェイ プタスズニク
アンドジェイ プタスズニク
ステファン パンドル
ステファン パンドル
ハング ファム
ハング ファム
Original Assignee
シーダーズ−サイナイ メディカル センター
シーダーズ−サイナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーダーズ−サイナイ メディカル センター, シーダーズ−サイナイ メディカル センター filed Critical シーダーズ−サイナイ メディカル センター
Publication of JP2017527615A publication Critical patent/JP2017527615A/ja
Publication of JP2017527615A5 publication Critical patent/JP2017527615A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017531467A 2014-09-02 2015-09-02 線維化疾患及び癌を治療するための組成物及び方法 Pending JP2017527615A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462044675P 2014-09-02 2014-09-02
US62/044,675 2014-09-02
PCT/US2015/048202 WO2016036886A1 (en) 2014-09-02 2015-09-02 Compositions and methods for treating fibrosing disorders and cancer

Publications (2)

Publication Number Publication Date
JP2017527615A true JP2017527615A (ja) 2017-09-21
JP2017527615A5 JP2017527615A5 (enExample) 2018-10-04

Family

ID=55440352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017531467A Pending JP2017527615A (ja) 2014-09-02 2015-09-02 線維化疾患及び癌を治療するための組成物及び方法

Country Status (4)

Country Link
US (1) US20180221369A1 (enExample)
EP (1) EP3188800A4 (enExample)
JP (1) JP2017527615A (enExample)
WO (1) WO2016036886A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017212021A1 (en) * 2016-06-10 2017-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
CA3068281A1 (en) * 2017-06-23 2018-12-27 Yale University Compositions and methods for efficacy enhancement of t-cell based immunotherapy
WO2020243063A1 (en) * 2019-05-25 2020-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Pi3k/lyn-acly signaling inhibition
US11184294B1 (en) * 2020-12-04 2021-11-23 Capital One Services, Llc Methods and systems for managing multiple content delivery networks
CN113350346B (zh) * 2021-06-01 2023-06-27 广西医科大学第一附属医院 长春新碱在预防或治疗心肌纤维化中的应用
CN117159520A (zh) * 2023-08-17 2023-12-05 中国人民解放军海军军医大学第一附属医院 竹红菌甲素在制备抑制胰腺纤维化的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121952A1 (en) * 1997-05-21 2004-06-24 Children's Medical Center Corporation Treatment of cancer
RS55740B1 (sr) * 2006-10-02 2017-07-31 Squibb & Sons Inc Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
US9062066B2 (en) * 2010-05-26 2015-06-23 Korea Institute Of Science And Technology Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
US20130203817A1 (en) * 2012-02-08 2013-08-08 Vassa Informatics Novel Inhibitors of LYN Kinase
US20140080772A1 (en) * 2012-09-06 2014-03-20 The Board Of Regents Of The University Of Texas System Treatments for melanoma

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ＢＬＯＯＤ, vol. 109, no. 1, JPN6019029701, 2007, pages 306 - 314, ISSN: 0004224586 *
ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＯＮＣＯＬＯＧＹ, vol. 29, no. 6, JPN6019029695, 2006, pages 1453 - 1458, ISSN: 0004224583 *
ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＩＮＶＥＳＴＩＧＡＴＩＯＮ, vol. 117, no. 1, JPN6019029706, 2007, pages 50 - 59, ISSN: 0004224588 *
ＪＯＵＲＮＡＬ ＯＦ ＨＥＰＡＴＯＬＯＧＹ, vol. 55, no. 3, JPN6019029704, 2011, pages 612 - 625, ISSN: 0004224587 *
ＪＯＵＲＮＡＬ ＯＦ ＭＯＬＥＣＵＬＡＲ ＭＥＤＩＣＩＮＥ, vol. 83, no. 10, JPN6019029708, 2005, pages 795 - 805, ISSN: 0004087112 *
ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＯＬＯＧＹ ＡＮＤ ＥＸＰＥＲＩＭＥＮＴＡＬ ＴＨＥＲＡＰＥＵＴ, vol. [online], JPN6019029693, 21 July 2014 (2014-07-21), pages 10 - 1124, ISSN: 0004224582 *
ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＯＬＯＧＹ ＡＮＤ ＥＸＰＥＲＩＭＥＮＴＡＬ ＴＨＥＲＡＰＥＵＴ, vol. 349, no. 2, JPN6019029697, May 2014 (2014-05-01), pages 209 - 220, ISSN: 0004224584 *
ＭＯＬＥＣＵＬＡＲ ＯＮＣＯＬＯＧＹ, vol. 3, no. 3, JPN6019029690, 2009, pages 248 - 261, ISSN: 0004224581 *
ＰＡＮＣＲＥＡＳ, vol. 43, no. 5, JPN6019029699, July 2014 (2014-07-01), pages 768 - 776, ISSN: 0004224585 *

Also Published As

Publication number Publication date
EP3188800A1 (en) 2017-07-12
US20180221369A1 (en) 2018-08-09
WO2016036886A1 (en) 2016-03-10
EP3188800A4 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
Dong et al. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer
CN102510719B (zh) 用与细胞毒性化学治疗剂组合的内皮素受体抑制剂治疗脑转移
US20220211706A1 (en) Methods and Compositions for Treating Cancer
Boado RNA interference and nonviral targeted gene therapy of experimental brain cancer
JP2017527615A (ja) 線維化疾患及び癌を治療するための組成物及び方法
BR112021012715A2 (pt) Silenciamento de tgf-beta 1 e cox2 usando sirnas entregues em combinação com inibidores imune checkpoint para tratar câncer
JP2024023290A (ja) がんの治療のための方法および組成物
EP3833760A1 (en) Microrna-based therapy targeted against lcp-1 positive cancers
Ji et al. CAT3, a prodrug of 13a (S)-3-hydroxyl-6, 7-dimethoxyphenanthro [9, 10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression
Ma et al. GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-Type Ovarian Cancer to PARP Inhibition
CN112423748A (zh) 一种用于治疗癌症的配方和方法
Tadic et al. An RNA vaccine against adrenomedullin reduces angiogenesis and tumor burden in a syngeneic metastatic melanoma mouse model
US20200188410A1 (en) Cxcr7 inhibitors for the treatment of cancer
Saxena et al. Anti-miRNA therapeutics for uterine fibroids
US20200023038A1 (en) Method of treating neoplasias
US20250281609A1 (en) Composition for treating or preventing cancer
WO2007051316A1 (en) Inhibition of autophagy genes in cancer chemotherapy
Bastola et al. Tumor edge architecture in glioblastoma is constructed by inter-cellular signals from vascular endothelial cells
Guo et al. Primary resistance to EGFR inhibition in glioblastoma is mediated by a TNF-JNK-Axl-ERK signaling axis
CN114617969B (zh) 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
Cabanas et al. EXTH-56. CSF PENETRATION COMPARISON OF TWO ORAL FORMULATIONS OF APL-101 IN A PRE-CLINICAL NON-HUMAN PRIMATE MODEL
Wan et al. Engineered lung cell targeting and SLC7A11 siRNA expressing bacterial extracellular vesicles impair the progression of none‐small cell lung cancer
WO2018160699A1 (en) Biomarkers for diagnosis, prediction and/or prognosis of pancreatic cancer and uses thereof
US8980863B2 (en) Modulation of radiation response using microrna
CN116271056A (zh) 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200304